Form 8-K - Current report:
SEC Accession No. 0002019410-25-000026
Filing Date
2025-11-05
Accepted
2025-11-05 16:17:48
Documents
13
Period of Report
2025-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cai-20251105.htm   iXBRL 8-K 28239
2 EX-99.1 cai_ex99-1.htm EX-99.1 277806
  Complete submission text file 0002019410-25-000026.txt   450882

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cai-20251105.xsd EX-101.SCH 1809
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cai-20251105_lab.xml EX-101.LAB 23435
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cai-20251105_pre.xml EX-101.PRE 13600
15 EXTRACTED XBRL INSTANCE DOCUMENT cai-20251105_htm.xml XML 2915
Mailing Address 750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TX 75039
Business Address 750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TX 75039 (866) 771-8946
Caris Life Sciences, Inc. (Filer) CIK: 0002019410 (see all company filings)

EIN.: 852077369 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42706 | Film No.: 251454291
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)